← Back to Search

Sodium-Glucose Cotransporter-2 Inhibitor

Treatment A for Type 1 Diabetes

Phase 1 & 2
Waitlist Available
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men and women between the ages of 18 and 65 years old, inclusive, at the time of screening;
Females of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study and for an additional 3 months after the end of dosing with the investigational product;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-weeks
Awards & highlights

Study Summary

This trial is testing a new diabetes treatment that could improve blood sugar levels.

Eligible Conditions
  • Type 1 Diabetes

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Beta-hydroxybutyrate (BHB) Level
Change in Glycemic Control
Change in Vascular Endothelial Function

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Treatment AActive Control2 Interventions
Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 35mg in 1mL solution REMD-477
Group II: Treatment BPlacebo Group2 Interventions
Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 1mL solution Placebo

Find a Location

Who is running the clinical trial?

JDRFUNKNOWN
3 Previous Clinical Trials
50,053 Total Patients Enrolled
University of California, San DiegoLead Sponsor
1,114 Previous Clinical Trials
1,519,868 Total Patients Enrolled
REMD Biotherapeutics, Inc.Industry Sponsor
6 Previous Clinical Trials
308 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025